evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

8 questions · 8 findings · 3 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 50%Low 1 · 12.5%Moderate 3 · 37.5%High 0 · 0%

Summary of findings table ‐ Convalescent plasma vs placebo or usual care

Serious adverse events ‐ total · individuals with moderate to severe disease

Summary of findings table ‐ Convalescent plasma showed no clear difference in serious adverse events ‐ total compared with placebo or standard care alone (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with placebo/no intervention (moderate certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

Summary of findings table ‐ Rifaximin showed no clear difference in serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharide (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin vs placebo or no intervention

Non‐serious adverse events ‐ total number of particiapnts · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin changes non‐serious adverse events ‐ total number of particiapnts compared with placebo/no intervention (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Rifaximin plus non‐absorbable disaccharides vs non‐absorbable disaccharide

Non‐serious adverse events ‐ total number of participants · prevention and treatment of hepatic encephalopathy in people with cirrhosis

It is very uncertain whether summary of findings table ‐ Rifaximin plus non‐absorbable… changes non‐serious adverse events ‐ total number of participants compared with non‐absorbable disaccharides alone (very low certainty).

1 finding from 1 review